Recombinant DNA technology is the process of joining together genetic material from two organisms that are not normally compatible. It allows creation of novel protein drugs by inserting human genes into microbial cells. These drugs offer safer alternative to conventional treatments. Recombinant DNA technology has revolutionized medicine by enabling mass production of insulin, human growth hormones and other therapeutics.
Market key trends:
Technological advancement is one of the key trends driving the growth of recombinant DNA technology market. Continuous research in genomics and gene sequencing has enabled development of advanced technologies like CRISPR that allow precise and easy modification of genomes. CRISPR technology has transformed genetic engineering by making DNA editing much cheaper, faster and more accurate. It is being widely used by biotech companies to develop new therapeutics. The declining cost of genome sequencing and gene synthesis is also promoting exploitation of full potentials of recombinant DNA technology. Enhanced technological capabilities are expected to accelerate discovery and development of novel biologics and gene therapies through recombinant DNA tools, thus fueling market growth over the forecast period.
Segment Analysis
The global recombinant DNA technology market is segmented by type into therapeutics, research, and industrial. Among these, the therapeutics segment held the largest market share owing to increasing demand for biologics and biosimilars for treating chronic diseases such as cancer and rare genetic disorders. Additionally, growing demand for vaccines and gene therapy is expected to drive the therapeutics segment during the forecast period.
Key Takeaways
The Global Recombinant DNA Technology Market Demand is expected to witness high growth. The global Recombinant DNA Technology Market is estimated to be valued at US$ 156.89 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030.
Regional analysis:
North America dominated the market for recombinant DNA technology and accounted for the largest revenue share. This is attributed to the growing research activities in biotechnology and pharmaceutical industries, increasing government funding for gene synthesis, and the strong presence of key biotech companies in the region. However, Asia Pacific is expected to grow at the fastest pace owing to rising investments by the governments and companies in biotechnology and bioscience sectors in emerging economies such as China and India.
Key players:
Key players operating in the recombinant DNA technology market are Fineheart, Berlin.
Fineheart offers a wide range of genetically engineered drugs and recombinant therapeutic proteins to treat various diseases. It has a strong presence across major markets. Berlin is a leading provider of gene synthesis services for research and industrial applications. It has collaborations with various biotech and pharmaceutical companies for gene therapy developments.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/recombinant-dna-technology-market-share-and-demand-analysis/
Explore more trending article on this topic -
https://www.pressreleasebulletin.com/recombinant-dna-technology-market-size-and-share-analysis/
Comments
0 comment